The successful use of intralesional IL-2 in the treatment of malignant tumours, including melanoma metastases (Gutwald et al, 1994a,1994b), squamous cell carcinoma (Whiteside et al, 1993), metastatic eccrine poroma (Dummer et al, 1992), malignant haemangioendothelioma (Inadomi et al, 1992), carcinoma erysipeloides (Hamamoto et al, 2001), and in newer times with PEG-IL-2 on basal cell carcinoma has only been published in single case reports (Kaplan and Moy, 2000). The gene discussed is IL2; the disease is melanoma.